OX40 & 4-1BB Costimulatory Antibodies: Agonist Research Reagents for Immuno-Oncology

While inhibitory checkpoints (PD-1, CTLA-4) are blocked to release the immune brake, costimulatory receptors (OX40, 4-1BB) are activated to press the immune accelerator.

Target Biology and Clinical Relevance

OX40 (CD134, TNFRSF4) and 4-1BB (CD137, TNFRSF9) are TNF receptor superfamily members expressed on activated T cells. Agonist antibodies that cross-link these receptors enhance T cell survival, proliferation, cytokine production, and memory formation.

Multiple OX40 and 4-1BB agonist antibodies are in clinical development as monotherapy and in combination with PD-1 blockade. 4-1BB is also a key signaling domain in CAR-T cell constructs (providing the costimulatory signal for T cell persistence).

Research applications include: agonist antibodies for T cell activation and co-stimulation assays, recombinant OX40L and 4-1BBL proteins as natural ligand surrogates, anti-OX40/4-1BB detection antibodies for flow cytometry (activation marker analysis), and biosimilar agonist antibodies for preclinical efficacy studies.

abinScience offers both detection-grade antibodies (for phenotyping) and functional-grade antibodies (for agonism/blocking) against both targets.

abinScience Product Coverage

References

1. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252-264. doi: 10.1038/nrc3239

2. Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015;27(4):450-461. doi: 10.1016/j.ccell.2015.03.001

3. Wei SC, Duffy CR, Allison JP. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov. 2018;8(9):1069-1086. doi: 10.1158/2159-8290.CD-18-0367

All products are for research use only. For technical support, contact order@abinscience.com.